We present an integrated summary from statistical and pharmacological perspectives of pharmacokinetic/pharmacodynamic (PK/PD) modelling and its use in drug development and regulation for guiding appropriate dosing. An overview of the technical aspects of PK/PD modelling describes how structural models are constructed and refined using pharmacokinetic and pharmacodynamic principles and how random effects models are used to account for individual differences in desired (and undesired) responses due to patient characteristics. Lastly, we describe applications of PK/PD modelling for the purposes of drug labelling, for resolving a safety concern, and for improving therapeutic monitoring of anaesthetic depth during surgery.
Get full access to this article
View all access options for this article.
References
1.
Fleishaker JC , Ferry JJ.Pharmacokinetic-pharmacodynamic modeling in drug development: comments and applications. In: Derendorf H , Hochhaus G eds. Handbook of pharmacokinetic/pharmacodynamic correlation. Boca Raton, FL: CRC Press , 1995.
2.
Vozeh S.The International Conference on Harmonisation . European Journal of Clinical Pharmacology1995; 48: 173-175 .
3.
Rowland M , Tozer TN.Clinical pharmacokinetics: concepts and applications, 2nd edition. Malvern, PA: Lea & Febiger , 1989.
4.
Holford NHG , Sheiner LB.Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models . Clinical Pharmacokinetics1981; 6: 429-453 .
5.
Peck CC , Barr WH , Benet LZet al.Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development . Clinical Pharmacology and Therapeutics1992; 51: 465-473 .
6.
Sheiner LB.Learning versus confirming in clinical drug development . Clinical Pharmacology and Therapeutics1997; 61: 275-291 .
7.
Kleinbloesem CH , van Brummelen P , Danhof M , Faber H , Urquhart J , Breimer DD.Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans . Clinical Pharmacology and Therapeutics1987; 41: 26-30 .
8.
Guidance for Industry: Population pharmacokinetics. US Department of Health and Human Services. Rockville, MD: Food and Drug Administration. Center for Drug Evaluation and Research, 1999 (http://www.fda.gov/cder/guidance/index.htm).
9.
Beal SL , Sheiner LB.NONMEM user's guides. University of California, San Francisco, CA: NONMEM Project Group , 1992.
10.
Davidian M , Giltinan DM.Nonlinear models for repeated measurement data. London: Chapman & Hall , 1995.
11.
Gibaldi M , Perrier D.Pharmacokinetics. New York: Marcel Dekker , 1982.
Sharma A , Jusko WJ.Characteristics of indirect pharmacodynamic models and applications to clinical drug responses . British Journal of Clinical Pharmacology1998; 45: 229-239 .
17.
Steimer JL , Mallet A , Golmard J , Boisieux J.Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effect model . Drug Metabolism Reviews1984; 15: 265-292 .
18.
Lindstrom MJ , Bates DM.Nonlinear mixed models for repeated measures data . Biometrika1990; 46: 673-687 .
19.
Pinheiro JC , Bates DM.Approximations to the log-likelihood function in the nonlinear mixed effects model . Journal of Computational and Graphical Statistics1995; 4: 12-35 .
20.
Racine-Poon A , Wakefield J.Statistical methods for population pharmacokinetic modelling . Statistical Methods in Medical Research1998; 7: 63-84 .
21.
Mallet A.A maximum likelihood estimation method for random coefficient regression models . Biometrika1986; 73: 3-3, 645-656 .
22.
Schumitzky A.Nonparametric EM algorithms for estimating prior distributions . Applied Mathematics and Computation1991; 45: 141-157 .
23.
Davidian M , Gallant AR.The nonlinear mixed effects model with a smooth random effects density . Biometrika1993; 80: 475-488 .
24.
D'Argenio DZ , Schumitzky A.A program package for simulation and parameter estimation in pharmacokinetic systems . Computer Programs in Biomedicine1979; 9: 115-134 .
25.
Sheiner LB.Analysis of pharmacokinetic data using parametric models. II. Hypothesis tests and confidence intervals . Journal of Pharmacology and Biopharmaceutics1986; 14: 539-555 .
26.
Mandema JW , Verotta D , Sheiner LB.Building population pharmacokinetic pharmacodynamic models. In: D'Argenio DZ ed. Advanced pharmacokinetic and pharmacodynamic systems analysis. New York: Plenum Press ,1995: 69-86.
27.
Efron B , Tibshirani RJ.An introduction to the bootstrap. London: Chapman & Hall , 1993.
28.
Efron B.Estimating the error-rate of a prediction rule: improvements on cross-validation . Journal of the American Statistical Association1983; 78: 316-331 .
29.
Forrest A , Hawtoff J , Egorin MJ.Evaluation of a new program for population PK/PD analysis: applied to simulated Phase I data . Clinical Pharmacology and Therapeutics1991; 49: 153-153 .
30.
Medical Economics Company . Physician's desk reference. Montvale NJ: Medical Economics Company , 1998.
31.
Wang D , Miller R.Pharmacokinetics of piroxicam. East Coast NONMEM Users' Group (Abstract), April, 1998.
32.
Sheiner LB , Beal SL , Dunne, A.Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials . Journal of the American Statistical Association1997; 92: 1235-1255 .
33.
Fadiran E , Miller R , Ludden T , Karkowsky A , Parekh A , Ferry J.Population pharmacokinetics (PK)-pharmacodynamics (PD) of minoxidil (MNX) . Clinical Pharmacology and Therapeutics1997; 61: 206-206 .
34.
Hu C , Lovejoy WS , Shafer SL.Comparison of some control strategies for three-compartment PK/PD models . Journal of Pharmacology and Biopharmaceutics199422: 525-550 .
